Iprivask is a drug owned by Canyon Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 31, 2015. Details of Iprivask's patents and their expiration are given in the table below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
US5733874 | Stable dry powders |
Mar, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Iprivask is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Iprivask's family patents as well as insights into ongoing legal events on those patents.
Iprivask's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Iprivask's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 31, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Iprivask Generics:
There are no approved generic versions for Iprivask as of now.
About Iprivask
Iprivask is a drug owned by Canyon Pharmaceuticals Inc. Iprivask uses Desirudin Recombinant as an active ingredient. Iprivask was launched by Canyon in 2003.
Approval Date:
Iprivask was approved by FDA for market use on 04 April, 2003.
Active Ingredient:
Iprivask uses Desirudin Recombinant as the active ingredient. Check out other Drugs and Companies using Desirudin Recombinant ingredient
Dosage:
Iprivask is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
Strength | Dosage Form | Availability | Application Pathway |
---|---|---|---|
15MG/VIAL | INJECTABLE | Prescription | SUBCUTANEOUS |